A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Emricasan (Primary)
- Indications Liver cirrhosis; Liver failure
- Focus Pharmacokinetics
- Sponsors Conatus Pharmaceuticals
- 08 Apr 2015 According to a Conatus Pharmaceuticals media release, detailed results from this trial will be presented in a late-breaker poster at The International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL).
- 11 Mar 2015 According to a Conatus Pharmaceuticals media release, aggregate top-line results from this and two other phase I trials, (n=73) in five distinct organ impairment patient populations were released in Jan 2015.
- 01 Oct 2014 Planned End Date changed from 1 Nov 2014 to 1 Mar 2015, as per ClinicalTrials.gov record.